Related Experiment Video

Updated: Aug 18, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Angiotensin converting enzyme insertion/deletion polymorphism does not influence postcardiac transplantation

J E Fildes1, A H Walker, C G Densem

  • 1Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom.

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|March 31, 2005
PubMed

Insights

This study found no link between the angiotensin converting enzyme (ACE) insertion deletion (I/D) polymorphism and hypertension after heart transplantation. Neither recipient nor donor ACE genotype influenced blood pressure or antihypertensive medication use.

Area of Science:

  • Cardiovascular Genetics
  • Transplantation Medicine
  • Pharmacogenomics

Background:

  • Posttransplantation hypertension is a significant complication following cardiac transplantation.
  • The angiotensin converting enzyme insertion deletion (ACE I/D) polymorphism has been implicated in cardiovascular diseases.

Purpose of the Study:

  • To investigate the association between the ACE I/D polymorphism and the development of posttransplantation hypertension in cardiac transplant recipients.

Main Methods:

  • Genotyping for the ACE I/D polymorphism in 211 heart transplant recipients and 154 donors using polymerase chain reaction.
  • Measurement of ACE enzymatic activity and blood pressure.
  • Analysis of clinical data including demographics and medications.

Main Results:

  • No significant differences were observed in antihypertensive medication use, cyclosporine levels, renal function, or blood pressure based on recipient or donor ACE genotypes.
  • No correlation was found between ACE enzymatic activity and blood pressure.

Conclusions:

  • This study, the largest of its kind in a cardiac transplantation population, found no relationship between ACE genotype and systemic hypertension.
  • The ACE I/D polymorphism does not appear to influence hypertension development or management post-cardiac transplant.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...